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Many patients with community-acquired pneumonia can be
treated on an outpatient basis, but a significant proportion of
patients require hospitalization for initiation of parenteral anti-
biotic therapy [1]. Patients with pneumonia may be converted
from parenteral antibiotic treatment to oral treatment after
3–5 days. Although outpatient parenteral treatment has been
shown to be effective in the therapy of community-acquired
pneumonia, early conversion to oral antibiotic treatment may
result in significantly fewer adverse events and reduction of
major costs. With the availability of newer oral b-lactam agents
with favorable pharmacokinetic and pharmacodynamic proper-
ties, the use of step-down therapy for lower respiratory tract
infections has increased in clinical medicine [2].
For most cases of community-acquired pneumonia requiring
hospitalization, the recommended regimens consist of a cepha-
losporin such as cefuroxime, cefotaxime or ceftriaxone, or a
penicillin plus a b-lactamase inhibitor with or without ery-
thromycin [1]. The most often isolated pathogenic bacteria are
Streptococcus pneumoniae, Haemophilus influenzae and Moraxella
catarrhalis. The recommended agents are active against these
pathogens.
Loracarbef, a synthetic b-lactam agent of the carbacephem
class for oral administration, has favorable pharmacokinetic,
pharmacodynamic and microbiological properties, which sug-
gests that this agent may be useful for early conversion from
parenteral treatment to oral treatment of community-acquired
pneumonia [3].
The most common and significant cause of disturbances in
the normal intestinal microflora is the administration of anti-
microbial agents [4]. When the number of microorganisms is
reduced during therapy, resistance to colonization is decreased,
which may lead to several unwanted effects. One is overgrowth
of already present microorganisms with natural resistance, such
as yeasts, which may cause systemic infections in immunocom-
promised patients, and Clostridium difficile, which may lead to
diarrhea and/or colitis. A second consequence is the establish-
ment of new resistant pathogenic bacteria, which may also
colonize other areas of the host. A third effect is the fact that
bacterial overgrowth also encourages the transfer of resistance
factors among bacteria. Several factors influence the extent to
which a given antimicrobial agent will reduce the normal
microflora. Predominant among these factors is the incomplete
absorption of agents perorally administered. Poorly absorbed
drugs can reach the colon in active form, where they suppress
susceptible microorganisms and disturb the ecological balance.
Antimicrobial drugs that are secreted in the bile or from the
intestinal mucosa also tend to affect the normal intestinal
microflora.
Loracarbef is approximately 90% absorbed from the gastro-
intestinal tract after oral administration, and only a minor impact
on the intestinal microflora has been reported [5,6]. In contrast,
parenteral ceftriaxone is excreted in the bile in high concen-
trations, resulting in major changes of the intestinal microflora
[7–9].
 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 369–393
376 Clinical Microbiology and Infection, Volume 7 Number 7, July 2001
The aim of the present investigation was to compare the
ecological effect of step-down therapy of ceftriaxone plus
loracarbef versus parenteral therapy of ceftriaxone on the
intestinal microflora in patients with community-acquired
pneumonia.
Twenty-four newly hospitalized patients (16 males and eight
females; mean age 62 years; age range 32–84 years) with com-
munity-acquired pneumonia participated in this prospective,
randomized, multicenter study in Germany (two hospitals) and
Sweden (two hospitals). Five patients in Sweden received
ceftriaxone plus loracarbef and five patients ceftriaxone. In
Germany, seven patients were treated with ceftriaxone plus
loracarbef and seven patients with ceftriaxone. Patients on
antibiotic treatment within 6 days before enrollment were
excluded. The inclusion criteria were age >18 years, informed
consent and disease diagnostic criteria. The patient should have
both presence of a radiographic pulmonary infiltrate and acute
onset of at least one clinical finding: (1) cough, (2) dyspnea, (3)
pleuritic chest pain, (4) sputum production, (5) fever >38 8C,
and (6) altered mental status. Clinical examinations were made
pre-therapy, during therapy (days 2 and 3), post-therapy (within
72 h of therapy completion), late post-therapy (10–14 days after
end of therapy), and very late post-therapy (21–28 days after end
of therapy). Sputum and blood cultures were obtained at the
same visits from all patients when indicated. Routine laboratory
tests were taken for hematology and blood chemistry. All
adverse events were reported to the investigators. Informed
consent was obtained from all patients, and the study was
approved by the local Ethics Committee.
Twelve patients received step-down therapy with ceftriaxone
(Roche, Basel, Switzerland) 1 g intravenously every 24 h for
2 days, followed by oral loracarbef (Eli Lilly, Indianapolis, USA)
400 mg every 12 h for 8 days. Twelve patients were given only
ceftriaxone 1 g intravenously every 24 h for 10 days.
Stool specimens were collected prior to antibiotic treatment
(day 0), during treatment (day 3), at the post-therapy visit
(day 12) and at the late post-therapy visit (day 24). The speci-
mens were collected in sterile plastic containers. The specimens
were frozen within 1 h and stored at 70 8C until assayed [10].
The microbiological analysis of the specimens was performed
as described by Edlund et al [10]. The stool specimens (1 g of
feces) were suspended in pre-reduced peptone–yeast extract
medium, diluted to 107 and inoculated on non-selective and
selective media. The following agar media were used: blood
agar (LabM Kemila, Bury, UK) for total aerobes and anaerobes,
CLED agar (Merck, Darmstadt, Germany) for detection of
Enterobacteriaceae, Enterococcosel agar (BBL, Cockeysville,
MD, USA) for detection of enterococci, Sabouraud agar (Difco,
Detroit, MI, USA) for detection of yeasts, Rogosa agar (Difco)
for cultivation of lactobacilli, BL agar (Bifidobacterium selective
agar; Difco) for cultivation of bifidobacteria, BKV (kanamycin–
vancomycin–blood agar) for cultivation of Bacteroides and
Prevotella spp., BNV agar (neomycin–vancomycin–blood agar)
for cultivation of fusobacteria, Veillonella agar (Difco) for cultiva-
tion of veillonella cocci, egg yolk agar (Oxoid, Basingstoke,
UK) for cultivation of clostridia, and TCCFA agar (Cycloserine
Cefoxitin Fructose agar; Peptone from Casein/Proteose Pep-
tonIII 40 mg/mL, sodium hydrogen phosphate 5 mg/mL,
potassium dihydrogenphosphate 1 mg/mL, sodium chloride
2 mg/mL, sodium sulfate 0.2 mg/mL, Bacto Agar/Agar-Agar
20 mg/mL, taurochloric acid 1 mg/mL, neutral red 0.03 mg/
mL, 15% fructose, Clostridium difficile supplement D-cycloserine,
cefoxitin) for detection of Clostridium difficile. The aerobic agar
plates were incubated for 48 h at 37 8C and the anaerobic plates
for 48 h at 37 8C in anaerobic jars (GasPak; BBL). After
incubation, different colony types were counted, isolated in
pure culture and identified to genus level. All isolates were
analyzed according to Gram reaction and cell and colony
morphology, followed by different biochemical tests. API
20E test kit (BioMe´rieux SA, Marcy l’Etoile, France) was used
for the identification of Enterobacteriaceae. The anaerobic
microorganisms were identified by gas–liquid chromatography
of metabolites from glucose. The lower limit of detection was
102 microorganisms/g feces.
The 12 patients treated with ceftriaxone had the following
respiratory findings: cough 10 patients, sputum production nine
patients, dyspnea eight patients, tachypnea nine patients, and
pleuritic chest pain six patients. The 12 patients treated with
ceftriaxone–loracarbef showed the following findings: cough 12
patients, sputum production seven patients, dyspnea eight
patients, tachypnea nine patients, and pleuritic chest pain six
patients. There were no differences in the respiratory diagnosis
criteria between the two treatment groups, and no differences
in clinical efficacy between the two groups.
The patients receiving ceftriaxone had the following bacter-
ial strains isolated from sputum on admission: Streptococcus
pneumoniae two strains, H. influenzae four strains, H. parain-
fluenzae four strains, Staphylococcus aureus two strains, and Sta-
phylococcus epidermidis one strain. Three patients in the
ceftriaxone group had two bacterial isolates (Streptococcus pneu-
moniae and H. parainfluenzae; H. influenzae and Staphylococcus
epidermidis; H. parainfluenzae and Staphylococcus aureus). In two
sputum samples at the first visit, no microorganisms were
isolated. In the ceftriaxone–loracarbef group, Streptococcus pneu-
moniae (one strain), H. influenzae (two strains), H. parainfluenzae
(six strains), Moraxella catarrhalis (one strain), Staphylococcus
aureus (one strain) and Staphylococcus epidermidis (two strains)
were recovered from the sputum samples at the first visit. In
the ceftriaxone–loracarbef group, three patients had two
bacterial isolates (H. parainfluenzae and Staphylococcus aureus;
H. parainfluenzae and Staphylococcus epidermidis; H. parainfluenzae
and Staphylococcus epidermidis). No microorganisms were found
in five samples, which may be due to previous antibiotic
treatment or sampling failure. Streptococcus pneumoniae was
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isolated from blood in one patient treated with ceftriaxone and
in one patient treated with ceftriaxone plus loracarbef. Seventeen
blood cultures in 24 patients were negative at the first visit. All
isolated bacterial strains were considered to be pathogenic for
the patients’ pneumonia. Patients with Chlamydia pneumoniae,
Mycoplasma pneumoniae and Legionella pneumophila were not
included in the study.
Figure 1 shows the impact of ceftriaxone on the aerobic
intestinal microflora. The numbers of Escherichia coli decreased
markedly, while the numbers of enterococci and Candida
increased during the therapy and post-therapy visits. The
microflora was normalized in most patients at the very late
post-therapy visit. The anaerobic intestinal microflora was also
affected (Figure 2). Lactobacilli, bifidobacteria and clostridia
but not Bacteroides strains were suppressed during and after
ceftriaxone treatment but returned to normal levels after
24 days.
The aerobic intestinal microflora was affected in a similar way
by the step-down treatment with ceftriaxone and loracarbef
(Figure 1). Figure 2 presents the effect on the anaerobic intest-
Figure 1 Impact of ceftriaxone ( ) and ceftriaxone plus loracarbef ( )
treatment on the intestinal aerobic microflora in 24 patients. Solid line,mean
value of the logarithmic number of microorganisms/g feces in patients
receiving ceftriaxone. Dashed line, mean value of the logarithmic number of
microorganisms/g feces in patients receiving ceftriaxone plus loracarbef.
Figure 2 Impact of ceftriaxone ( ) and ceftriaxone plus loracarbef ( )
treatment on the intestinal anaerobic microflora in 24 patients. Solid line,
mean value of the logarithmic number ofmicroorganisms/g feces inpatients
receiving ceftriaxone. Dashed line, mean value of the logarithmic number of
microorganisms/g feces in patients receiving ceftriaxone plus loracarbef.
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inal microflora. Lactobacilli, bifidobacteria and clostridia were
suppressed significantly, while Bacteroides strains were not mark-
edly affected by the ceftriaxone–loracarbef treatment. Three
patients had Clostridium difficile strains during treatment. The
intestinal microflora was normalized after 24 days. When com-
paring the two treatment groups, no differences were observed
during the first 2 days of treatment. No statistical differences in
the effect on the intestinal microflora between the two treat-
ment regimens were observed.
Loracarbef is a b-lactam antibiotic for oral administration. It
is 90% absorbed from the gastrointestinal tract after oral admin-
istration with or without food. As a result of the absorption,
minor changes in the intestinal microflora after loracarbef
administration have been observed [5]. The stool concentra-
tions of loracarbef are also low, 0–0.9 mg/kg after administra-
tion of loracarbef 200 mg twice daily for 7 days [5]. In contrast,
ceftriaxone is excreted in high concentrations in the bile
(500 mg/L), and pronounced effects on the aerobic and anae-
robic microflora have been reported [7,11].
Ceftriaxone is used in the outpatient treatment of commu-
nity-acquired pneumonia in children and adults with clinical
success [12,13]. However, in order to reduce the ecological
impact of ceftriaxone on the intestinal microflora and the
duration of hospitalization, step-down therapy with an oral
b-lactam agent may be preferable. In the present trial, loracarbef
was used as the oral agent. There was no difference in the
clinical efficacy between the two 12-patient treatment groups,
indicating that step-down therapy of ceftriaxone plus loracarbef
for treatment of community-acquired pneumonia may be
acceptable. However, it should be mentioned that only a small
number of patients were participating in the trial.
In conclusion, step-down therapy with ceftriaxone plus
loracarbef caused similar ecological alterations in the intestinal
microflora to those of parenteral ceftriaxone therapy in patients
with community-acquired pneumonia.
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Infection of implanted plastic devices is one of the most serious
complications in hospitalized patients [1]. The genus Candida
comprises important nosocomial pathogens involved in biofilm
production on catheter and prosthetic materials. The ability of
many strains of the genus Candida to adhere to inert polymeric
surfaces may allow these microorganisms direct access into the
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